Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer

NCT04247035 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-02-10

No results posted yet for this study

Summary

• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

Conditions

Sponsors & Collaborators

  • Hellenic Society of Medical Oncology

    lead OTHER

Principal Investigators

  • Ioannis Boukovinas, Dr /Phd · HeSMO

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2022-01-31
Completion
2024-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04247035 on ClinicalTrials.gov